A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
Verve Therapeutics, Inc.
85 participants
Apr 30, 2024
INTERVENTIONAL
Conditions
Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Eligibility
Inclusion Criteria1
- Diagnosis of HeFH or premature CAD
Exclusion Criteria4
- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous (IV) infusion
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06164730